🇺🇸 FDA
Pipeline program

eN-Lac®

MA0809005101

Phase 3 mab completed

Quick answer

eN-Lac® for Perennial Allergic Rhinitis is a Phase 3 program (mab) at Biotech Pharmaceutical Co., with 1 ClinicalTrials.gov record(s).

Program details

Company
Biotech Pharmaceutical Co.,
Indication
Perennial Allergic Rhinitis
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials